The magnitude and timing of recalled immunity after breakthrough infection is shaped by SARS-CoV-2 variants

Article activity feed

1. Version published to 10.1016/j.immuni.2022.05.018

   Jul 1, 2022
2. 

   ScreenIT

   Dec 28, 2021

   SciScore for 10.1101/2021.12.23.21268285: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   NIH rigor criteria are not applicable to paper type.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   After three washes in PBST (PBS with 0.05% Tween-20), wells were incubated with 100µl of rabbit polyclonal anti-SARS-CoV N antibody (Rockland, #200-401-A50) at a 1:8000 dilution in dilution buffer (PBS with 0.2% Tween-20, 0.1% BSA and 0.5% NP-40) for 1 hour.	anti-SARS-CoV N suggested: (Rockland Cat# 200-401-A50, RRID:AB_828403)
   Monoclonal antibodies for surface staining included CD19-ECD (J3-119, 1:150) (Beckman Coulter), IgM BUV395 (G20-127, 1:150), CD21 BUV737 (B-ly4, 1:150), IgG BV786 (G18-145, 1:75), streptavidin-BV510 (1:600), CD11c (B-ly6,	G20-127 suggested: (BD Biosciences Cat# 740998, RRID:AB_2740…

   SciScore for 10.1101/2021.12.23.21268285: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   NIH rigor criteria are not applicable to paper type.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   After three washes in PBST (PBS with 0.05% Tween-20), wells were incubated with 100µl of rabbit polyclonal anti-SARS-CoV N antibody (Rockland, #200-401-A50) at a 1:8000 dilution in dilution buffer (PBS with 0.2% Tween-20, 0.1% BSA and 0.5% NP-40) for 1 hour.	anti-SARS-CoV N suggested: (Rockland Cat# 200-401-A50, RRID:AB_828403)
   Monoclonal antibodies for surface staining included CD19-ECD (J3-119, 1:150) (Beckman Coulter), IgM BUV395 (G20-127, 1:150), CD21 BUV737 (B-ly4, 1:150), IgG BV786 (G18-145, 1:75), streptavidin-BV510 (1:600), CD11c (B-ly6,	G20-127 suggested: (BD Biosciences Cat# 740998, RRID:AB_2740621) CD21 suggested: (BD Biosciences Cat# 742764, RRID:AB_2741029) B-ly4 suggested: (BD Biosciences Cat# 740969, RRID:AB_2740594) G18-145 suggested: (BD Biosciences Cat# 563247, RRID:AB_2738093)
   An CD154 APC-Cy7 (TRAP-1, BD Biosciences) antibody was included in the culture medium for the duration of the stimulation.	TRAP-1 suggested: None
   After stimulation, cells were washed, stained with Live/Dead blue viability dye (Thermo Fisher) and incubated in a cocktail of monoclonal antibodies: CD27 BV510 (L128, 1:50), CCR7 Alexa700 (150503, 1:50)	CD27 suggested: None CCR7 suggested: None
   Surface stain antibodies included: CD45RA PerCP-Cy5.5 (HI100), CD4 BV605 (RPA-T4), CD3 BUV395 (SK7) and CD20 BUV805 (2H7) (BD Biosciences).	CD4 suggested: (Nanostring Cat# 121300104, RRID:AB_2893077) CD3 suggested: None CD20 suggested: (BD Biosciences Cat# 564917, RRID:AB_2744326)
   Experimental Models: Cell Lines
   Sentences	Resources
   Next, plasma-virus mixtures (50µl) were added to Vero cells in duplicate and incubated at 37°C for 48 hours.	Vero suggested: None
   Software and Algorithms
   Sentences	Resources
   IC50 values were determined using four-parameter nonlinear regression in GraphPad Prism with curve fits constrained to have a minimum of 0% and maximum of 100% neutralization.	GraphPad Prism suggested: (GraphPad Prism, RRID:SCR_002798)

   ---

   Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

   ---

   Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

   ---

   Results from TrialIdentifier: No clinical trial numbers were referenced.

   ---

   Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

   ---

   Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on pages 25, 26, 11 and 13. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.

   ---

   Results from rtransparent:

   • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
   • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
   • Thank you for including a protocol registration statement.

   ---

   Results from scite Reference Check: We found no unreliable references.

   ---

   Read the original source
3. 

   Version published to 10.1101/2021.12.23.21268285 on medRxiv

   Dec 23, 2021